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Abstract
Background: Bone marrow mononuclear cells (MNC) represent an investigational treatment for stroke. The objective of this
study was to determine the relevance of vasoactive mediators, generated in response to MNC injection, as factors regulating
cerebral perfusion (CP), the biodistribution of MNC, and outcome in stroke.
Methods: Long Evans rats underwent transient middle cerebral artery occlusion. MNC were extracted from the bone
marrow at 22 hrs and injected via the internal carotid artery or the femoral vein 2 hours later. CP was measured with MRI or
continuous laser Doppler flowmetry. Serum samples were collected to measure vasoactive mediators. Animals were treated
with the Nitric Oxide (NO) inhibitor, L-NAME, to establish the relevance of NO-signaling to the effect of MNC. Lesion size,
MNC biodistribution, and neurological deficits were assessed.
Results: CP transiently increased in the peri-infarct region within 30 min after injecting MNC compared to saline or fibroblast
control. This CP increase corresponded temporarily to serum NO elevation and was abolished by L-NAME. Pre-treatment with
L-NAME reduced brain penetration of MNC and prevented MNC from reducing infarct lesion size and neurological deficits.
Conclusions: NO generation in response to MNC may represent a mechanism underlying how MNC enter the brain, reduce
lesion size, and improve outcome in ischemic stroke.
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Introduction
Experimental findings suggest various stem cells and other types
of cells may reduce brain damage caused by ischemic injury in
animal stroke models [1–3]. Cells originating in bone marrow are
one of many different cellular sources that have been shown to
improve outcome in animal models of middle cerebral artery
occlusion (MCAO). Mononuclear cells (MNCs) for autologous
transplantation can be isolated within hours of bone marrow
aspiration for immediate use unlike mesenchymal stem cells that
require several weeks of growth in culture for purification.
MNCs improve outcome in animal models of cerebral ischemia
[4–6]possiblybyexertingcytoprotectiveeffectsandreducinginfarct
maturation [4]. Intravenous (IV) and intra-arterial (IA) injection
have been shown to deliver MNCs to the ischemic brain; however,
only a fraction of injected cells migrate to the brain while the rest
spread to other organs [6]. Increased number of MNCs in the brain
after stroke may contribute to better recovery. Thus more
information about the mechanisms governing the deposition and
biodistributionof thesecellsafterintravascularinjectionmayhelp to
optimize brain delivery of these cells and recovery after stroke. In
this study, we investigated the effects of intravascular injections of
MNCs on cerebral perfusion (CP) and found that MNC injection
transiently increases CP mediated, in part, by nitric oxide (NO). We
then assessed whether changes in perfusion associated with NO
affects the biodistribution of MNCs in the brain and other organs.
To determine whether changes in perfusion or MNC delivery to the
brain are functionally relevant, we investigated whether inhibiting
NO before MNC administration would interfere with the ability of
MNCs to promote tissue protection and neurological improvement
in the rodent stroke model.
Materials and Methods
Ethics Statement
All procedures were approved by the University of Texas-
Houston Health Science Center Animal Welfare Committee
(Protocol Number: HSC-AWC-08-103). All surgeries were
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32793performed under isoflurane (2%) anesthesia, and all efforts were
made to minimize any discomfort.
Animals
For this study, 116 Male Long Evans (0.6–0.8 kg) retired
breeder (10 month old) rats were used. All animals were double
housed with free access to food and water. Subjects were
maintained on a standard 12:12hrs light/dark cycle. Table 1
provides a summary of the different experiments in this report. For
all experiments, animals were randomized to treatment groups
and outcome assessments were completed blinded to treatment
allocations.
Stroke Model
Reversible focal ischemia of 180 min was induced by left
common carotid artery (CCA) and middle cerebral artery (MCA)
occlusion as previously described [4,7]. CP was monitored by
Laser Doppler Flowmetry (LDF) over the ischemic area [7]. Rectal
temperature was monitored and maintained at 3761uC during
ischemia and for the first hour of reperfusion using a feed-forward
temperature controller (YSI Model 72, Yellow Springs, OH) that
utilizes a heat lamp and warming blanket.
Delivery Routes
IA injection was performed through the internal carotid artery
as previously described [4]. For IV delivery, the right femoral vein
was cannulated.
Bone Marrow Harvest
Twenty-two hours after stroke, bone marrow was aspirated as
described previously [4]. MNC were separated from bone marrow
using Ficoll density [4]. After separation, MNC were resuspended
in 1 ml of saline at 10 million cells/ml for injection.
LDF Monitoring
Twenty-four hours after stroke, rats were anesthetized. To
monitor CP, the LDF probe was placed 6 mm posterior and
5 mm lateral to bregma, which overlies the peri-infarct region [7].
The average regional CP in 20 minutes before injection was
regarded as baseline and monitored continuously during the
injection and 30 min afterwards. The percent change from
baseline was calculated during injection and 1, 3, 5, 10, 15, 20,
and 30 min post injection.
Preparation of MNC supernatant
MNCs were collected as described elsewhere [4]. MNCs were
divided and seeded with a concentration of 10 million cells/ml in
Dulbecco’s Modified Eagle Medium (DMEM) (GIBCO, Invitro-
gen, USA)+10% fetal bovine serum (FBS). All cells were incubated
at 37uC. Medium was collected at different time points for
measurements of vasoactive mediators. Samples from 3 animals
were used in triplicate.
Fibroblast cell preparation
Rat fibroblast cells (FBCs) (CRL-1764, ATCC, USA) were
cultured and isolated as described elsewhere [8]. Briefly, one vial
of cells (,1610
6) was cultured in a 75 cm
2 flask in high glucose
DMEM (GIBCO, Invitrogen, USA), supplemented with 10% FBS
(Hyclone Laboratories, USA), 100 unit/ml penicillin, in a
humidified 5% CO2 incubator at 37uC with medium routinely
changed every three days. When cells were 95% confluent, they
were trypsinized with 0.25% trypsin+0.05% EDTA and resus-
pended in culture medium and counted. The cells were extensively
washed and 10 million/ml cells were re-suspended in saline for
treatment.
Preparation of blood serum
At different time points - before injection, during injection, and
at 0, 1, 5, 10, 15, 30, 45 and 60 min after injection, 0.3 ml whole
blood was harvested from the left external jugular vein. Samples
from 5 animals were used in triplicate.
Magnetic Resonance Imaging
Scans were performed on a 7T Bruker Biospec horizontal bore
scanner (USR70/30; Bruker, Germany) with a S116 gradient.
Animals were maintained on 2–2.5% isoflurane during the scan
and body temperature was maintained with a feedback-controlled
warm air system (SA Instruments, USA). The respiration, rectal
temperature, oxygen level, and heart rate were continuously
monitored. Images were acquired with dual-echo rapid acquisition
and relaxation enhancement (RARE) sequence [9]. MR contrast
was injected through femoral vein during the acquisition of
dynamic susceptibility contrast-enhanced perfusion weighted
Table 1. Experimental design.
Experiments Groups
MR perfusion (n=4 per group)
at 24 hrs after stroke
Saline IV MNCs IV MNCs IA
Laser Doppler Flow (n=6 per
group) at 24 hrs after stroke
Saline IV MNCs IV MNCs IA FBCs IV
Levels of NO and other
vasodilators (n=5 per group)
at 24 hrs after stroke
Saline IV MNCs IA MNCs IV Saline IP+SalineIV
(only NO)
Saline IP+
MNCs IV
(only NO)
L-NAME IP+MNCs IV
(only NO)
Biodistribution of MNCs (n=3
per group) at 1 hour after MNC
injection
Saline IP
+MNCs IV
L-NAME IP+MNCs IV
Lesion Size (n=8 per group) at
28 days after stroke
Saline
IP+Saline IV
Saline IP
+MNCs IV
L-NAME IP
+MNCs IV
Saline IV NONOate IV
Functional recovery (n=8 per
group) at 1, 3, 7, 14, 21, and 28
days after stroke
Saline
IP+Saline IV
Saline IP
+MNCs IV
L-NAME IP
+MNCs IV
Saline IV NONOate IV
doi:10.1371/journal.pone.0032793.t001
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from the perfusion weighted imaging (PWI) data using BioMAP
Software (Bruker, Germany) and NIH’s Image J software. The
diffusion weighted imaging (DWI) maps were superimposed on the
PWI maps by co-registering the two images. Five regions of
interests (ROIs) were placed at the boundary just outside the lesion
identified as the demarcated area that had restricted diffusion on
DWI. This area just outside the DWI lesion was considered the
peri-infarct region. Image slices were selected randomly and the
mean TTP of the ROIs was reported. MRI was performed
immediately before MNC infusion and repeated at 5 minutes after
infusion of MNCs.
Vasoactive Mediators
NO was assessed by measuring nitrite level using the Griess
Reagent method (Biotium, USA). 150 ml of supernatant from
MNC containing media or blood serum were incubated at
different time points. The level of histamine released into the
media containing MNC in vitro and blood serum in vivo at
different time-points was determined by using a competitive direct
Enzyme-linked immunosorbent assay (ELISA) (CD-ELISA) (His-
tamine EIA Kit, Oxford Biomedical Research, UK). The level of
PGI2 released into the media containing MNC in vitro and blood
serum in vivo was determined with the measurement of 2,3-dinor-
6-keto PGF 1a using an ELISA kit (EIA Kit, Cayman Chemical,
USA).
NOS Inhibitor
NO production was inhibited using L-NAME (50 mg/kg, Alexis
Biochemicals, USA) in 1 ml of Phosphate buffered saline (PBS).
Rats underwent stroke and at 22 hrs, MNCs were collected. At
1 hour prior to MNC or saline injection, L-NAME was
administered by intraperitoneal injection (IP) while the control
group received saline IP.
NO Donor
To promote NO generation, the NO donor, MAHMA
NONOate, ([Z]-1-[N-(2-aminoethyl)-N-(2-ammonioethyl) aminio]
diazen-1-ium-1,2-diolate) (0.4 mg/kg, Sigma-Aldrich, USA) in
1 ml PBS was used. Rats underwent stroke and were then
randomized 24 hrs later to receive saline or NONOate IV.
Biodistribution
After stroke and bone marrow harvest at 22 hrs, MNC were
labeled with Q-tracker525 (Green). At one hour prior to MNC
injection, animals were administered L-NAME (50 mg/kg) or
saline (N=3 per group) IP. Ten million labeled autologous MNCs
were administered IV at 24 hrs after stroke. At one hour after
MNC injection, animals were sacrificed and perfused with cold
PBS followed by 4% paraformaldehyde (PFA). The brain, lungs
and spleen were removed and post-fixed for 24 hours and then
immersed in 20% sucrose. Ten micron cryosections were
generated and counterstained with 49,6-diamidino-2-phenylindole
(DAPI) (blue) prior to microscopic analysis. Q-tracker positive
MNCs were quantified with NIH image software (Image J) in each
experimental group on 3 sections of predefined ROIs, involving 9
fields per section randomly chosen under 4006 magnification.
The regions of interest were in the lungs, spleen, and in the peri-
injured tissue of the brain at the level of the striatum.
Lesion Size
Lesion size was determined in two sets of experiments. In
Experiment 1, animals were randomly allocated to the following
treatment groups at 1 day after stroke: (1) L-NAME IP followed by
10 million MNCs IV; (2) saline IP followed by 10 million MNCs
IV; or (3) saline IP followed by saline IV (N=8 per group). In
Experiment 2, animals were randomly assigned to the following
treatment groups at 1 day after stroke: (1) NONOate IV or (2)
Saline. At 28 days after stroke in both sets of experiments, rats
were deeply anesthetized and perfused transcardially with PBS,
followed by 4% PFA in PBS. Coronal 20 um frozen sections were
cut and stained with cresyl violet to measure tissue loss of the
chronic infarct using the indirect method and expressed as a
percentage of the contralateral hemisphere [10]. Outcomes were
measured blinded to treatment groups.
Behavioral Studies
In the same experiments above involving groups of animals that
underwent lesion size, all animals underwent sensorimotor testing
which was performed during the light cycle by an examiner
blinded to treatment allocation. Animals were pre-tested and then
tested before MCAO and on days 1, 3, 7, 14, 21, 28 post-ischemia.
We used a battery of sensorimotor tests, a composite of motor,
sensory, and balance tests based on the modified Neurological
Severity Score (mNSS) sensitive to damage produced by our
rodent ischemia model and include the following [11].
1. Cylinder [4]: The final score was calculated as (non-impaired
forelimb touch+both touch)/total touch. A total of consecutive
20 touches were recorded in the 5- minutes test.
2. Circling: Animals were placed in a Plexiglas cylinder and the
ratio of circling movements toward the non-paretic to the
paretic side was recorded in the 2-min test.
3. Tactile Placing [12]: The number of times the rat successfully
raised its forelimb to the tabletop after whiskers contacted the
top surface was scored. 10 trials62 times for each side and then
the average were obtained. Value=non-impaired side –
impaired side.
4. Sticker Test [11]: the time to removal of a sticker placed on the
right and left forepaws was recorded within an observation
time of 180 seconds. The time to removal on the right forepaw
was subtracted from the time on left forepaw.
5. Beam Balance [11]: using a beam with 2-cm width and 150 cm
length
6. Flexing Test [11]:Raising rat by the tail
Table 2 shows the details of different tests and scores. Outcomes
were measured blinded to treatment groups.
Statistics
All data are presented as Mean6SD. Statistical significance was
set at p,0.05 level. Statistical analysis was performed with
repeated-measures ANOVA and post hoc tests for continuous
variables. Behavioral data are presented as median6SD. Statis-
tical analysis was performed with ranked sum repeated measures
testing.
Results
Mortality
The overall mortality was 3% and occurred in the behavioral
studies (4/44=9%). Four animals died in the first 24 hours after
stroke prior to allocation to treatment groups. As we have shown
in a prior report [4], there was no mortality associated with intra-
arterial delivery of MNCs.
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We found a significant decrease in TTP within the peri-infarct
area at 5 minutes after MNC injection compared with saline
injection. This effect was observed in both the IA and IV MNC-
treated groups (p=0.03 and p=0.04, respectively) compared to
the TTP values before injection (Figure 1A), indicating that these
cells increase CP. To verify the observed increase in CP induced
by MNCs with MRI at this time point, another group of animals
were monitored using LDF over the peri-infarct area, which
confirmed the findings of increased CP induced by MNC detected
on MR perfusion (Figure 1B). We then assessed using LDF the
duration of perfusion changes after injection of MNC in the peri-
infarct area (Figure 1C) in the same experiment. CP was
significantly increased by MNC from 1 to 15 minutes after
injection. To assess whether the effect on perfusion is unique to
MNCs, corresponding groups of animals at 24 h after stroke either
received injections of saline or FBCs instead on MNCs. The FBC
and saline-treated groups did not show a change in cerebral
perfusion compared with baseline CP values (Figure 1C).
Vasoactive Mediators
We hypothesized that MNCs may affect CP through the direct or
indirect release of vasoctive mediators. To test this hypothesis, in a
separate experiment, we measured the serum level of NO
(Figure 2A), histamine, and PGI2 early after IA or IV injection
of MNCs or saline in rats at 24 hrs after stroke. Five minutes after
IV injection of MNCs, the NO level increased sharply and then
decreased over the next 25 min. NO levels returned to normal at
45 min post-injection. However, there was no change in PGI2 or
histamine levels (data not shown). To determine a causal
relationship between NO and CP, in parallel experiments, we
treated rats with the Nitric oxide synthase (NOS) inhibitor, L-
NAME, prior to receiving MNCs. This study demonstrated that L-
NAME significantly reduced the levels of serum NO compared with
animals pre-treated with saline (Figure 2B). We then investigated
whether MNCs are the source of NO by measuring its level in the
media used to culture these cells. We found no detectable levels of
NO present in the culture media collected at 1 min, 5 min, 15 min,
30 min, 45 min, 60 min, 2 hrs, 6 hrs, and 24 hrs after MNCs were
added to the media(data not shown),suggesting that the NO release
may require interaction of MNCs with the host tissue, and may
involve vascular cells of animals receiving MNCs.
MNC-induced changes in cerebral perfusion are
attenuated by NOS inhibitor
To test the hypothesis that NO contributes to the increase in
perfusion induced by MNCs, animals were pre-treated with L-
NAME or saline 10 minutes before IV injection of MNCs (10
million cells) at 24 h after stroke. In agreement with our data that
MNCs increase CP and lead to elevated NO levels, animals pre-
treated with L-NAME to inhibit NO synthesis no longer showed
an increase in CP on LDF compared to saline and pre-treatment
values (Figure 3).
Biodistribution
Assuming that NO, released in response to MNCs, underlies
increased CP and vasodilation, we hypothesized that these
vascular responses may be important for MNC delivery to the
brain. The same mechanisms may facilitate MNC transit through
the lung, which sequesters cells from the circulation [13], and
enhance their delivery to the brain. To examine the relevance of
NO to this process we used L-NAME, which we have shown
reduces serum NO levels under the same experimental conditions.
Specifically, we evaluated the biodistribution of MNCs intrave-
nously injected into the rat at 24 hrs after stroke (Figure 4).L -
NAME or saline was administered 1 hr before MNC injection. L-
NAME robustly reduced the number of MNCs in the peri-
ischemic brain as compared to saline control (8.563.5 vs 18.264.0
p,0.01; Figure 4B). L-NAME also reduced the number of
MNCs in the spleen (76.5616.0 vs 99.8616.1, p,0.01), however
it increased the number of MNCs in the lungs compared to saline
control (46.268.2 vs 33.567.1, p,0.05) (Figure 4B). Represen-
tative images of MNCs in brain, spleen and lung are shown in
(Figure 4A). There appeared to be more MNCs observed within
the lumen and wall of the pulmonary arteries in animals that were
pre-treated with L-NAME compared with saline (Figure 5).
Infarct Maturation
Although we found that MNCs increase CP transiently which is
associated with NO-dependent delivery of MNCs to the brain, the
question arises whether these findings have biological relevance to
the pathogenesis of ischemic stroke. We addressed this question by
determining if pre-treatment with L-NAME, which reduces MNC
entry to the brain, ameliorates the effects of MNC on the delayed
infarct maturation process after stroke, a phenomenon well
established in our laboratory for this stroke model [4]. First, we
confirmed that in animals treated with 10 million cells, there was a
significant reduction in ischemic lesion size at 28 days, as
compared with animals who received saline control (p,0.05).
Next, we showed that treatment with L-NAME one hour before
MNC infusion led to a loss in tissue protection (inhibition of a
lesion growth) (Figure 6A), suggesting that NO plays an
important role in mediating the cytoprotective effects of MNC
in the rodent stroke model. Finally, the beneficial role for NO in
the recovery process after stroke appears to be through facilitating
Table 2. Details of different behavioral tests and scores.
Score Circling Cylinder Tactile Placing Sticker Test Beam Balance Flexing Test
0 ,100% 0–50% ,2 ,20 s No limbs down for 60 sec no flexion of forelimb
1 .100% 50–60% 2 to 4 20 to 60 s Stays on beam for 60 sec but
1 limb falls
Flexion of forelimb
2 .150% 60–70% 5 to 7 60 to 90 s Stays on beam for 60 sec
but 2 limbs falls
NA
3 .200% 70–80% 8 to 10 90 to 120 s Falls off, .40 s NA
4 .250% 80–90% NA 120 to 150 s Falls off, 20–40 s NA
5 .300% 90–100% NA .150 s Falls off, ,20 s NA
doi:10.1371/journal.pone.0032793.t002
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on brain tissue preservation, as the administration of the NO
donor, NONOate, instead of MNC at 24 h after stroke, showed
no beneficial effect on lesion volume maturation or functional
deficits at 28 days (data not shown).
Neurological Deficits
To determine if brain damage at the later stages of infarct
maturation following treatment with L-NAME also affects func-
tional recovery after stroke, we analyzed neurological deficits. In the
same animals described above, we demonstrated that L-NAME in
addition to increasing brain damage, also reversed the beneficial
effect of MNC on neurological function, as determined at 28 days
after stroke (Figure 6B). The administration of the NO donor,
NONOate, however, at 24 h after stroke showed no effect on
neurologicaldeficits(datanot shown)comparedwith salinecontrols.
Discussion
MNCs are an attractive source for cell-based therapy because
they are easily isolated from bone marrow and permit autologous
Figure 1. Changes in Cerebral perfusion. (A) Perfusion weighted imaging was performed in animals receiving MNC or saline at 24 hrs after MCA
occlusion. There was a significant decrease ({p,0.05) in the mean TTP in the peri-infarct region at 5 minutes after MNC infusion via IA or IV routes of
delivery. There was no significant change in TTP in the saline group before and after injection. N=4 per group. (B) Cerebral perfusion (CP) was
monitored with Laser Doppler flowmetry over the peri-infarct area of animals administered MNCs (10 million cells) or saline at 24 hrs after MCA
occlusion. CP was expressed after injection as a percentage compared with the baseline pre-injection value. CP increased at 5 minutes after MNC
injection. There was no significant change in CP in the saline treated group. N=6 per group. (C): Time course of changes in cerebral perfusion after IV
injection of MNCs (10 million cells), FBCs (10 million), or saline. {p,0.05 refers to the MNC group compared to the saline group and 1p,0.05 refers to
the MNC group compared with the FBC group. There was significant elevation of CP after MNC infusion at 1, 3, 5, 10 and 15 minutes. There was no
significant change in CP in the saline or FBC groups. ‘0’ on x-axis represents the time in minutes, just before the injection. N=6 per group.
doi:10.1371/journal.pone.0032793.g001
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to the peri-infarct region, enhance recovery and reduce post-
ischemic lesion size [4,14]. We found that MNCs transiently
increase perfusion in the peri-infarct area when administered IA or
IV. However, we chose an IV delivery route for most of our
experiments because IV and IA were found to lead to similar
effects on MR perfusion and IA delivery of saline causes an
immediate decrease in LDF signal due to hemodilution in our
preliminary data. The increase in CP is likely mediated, at least in
part, by NO. The administration of MNCs leads to a rise in serum
NO within minutes of injection and the NO synthase inhibitor, L-
NAME, administered prior to MNCs attenuated both the increase
in NO level and CP caused by MNCs. These results suggest a
direct relationship between NO and the changes in MNC-induced
perfusion. Interestingly, we found no evidence for changes in the
serum of other vasoactive substances such as histamine or PGI2,
again suggesting a prominent role for NO in this process. Finally,
we have also demonstrated that the increase in CP after MNC
injection is unlikely the result of vascular responses to a sudden
increase in number of cell particles in the lumen as injection of an
equivalent number of fibroblasts did not change CP.
Prior studies have shown that MNCs can increase cardiac
perfusion weeks after administration due to an induction in
angiogenesis [15] and that MNCs can increase cerebral perfusion,
mediated by NO, in a global cerebral ischemia animal model [16].
Our data suggest a novel mechanism in which NO-mediated
improvement in CP may assist in the arterial passage of MNCs to
the peri-ischemic aspect of the brain, to a location where these
cells could favorably affect secondary stroke pathogenesis and the
recovery process. In agreement with this notion, we found that
NO synthase inhibition, which prevents MNC-mediated NO
formation and reduces CP, also adversely affected MNC’s access
to the brain as evidenced by a reduced number of MNCs in the
ischemic brain. Since previous studies suggest that a higher
number of MNCs in the brain corresponds to better functional
outcome [6], it is possible that this short NO-mediated facilitation
Figure 2. Time course of changes of NO at 24 hours after stroke. (A): Serum NO levels after saline or MNC (IV or IA) administered at 24 hrs
post stroke. 1p,0.05 for IA or IV MNC treated groups compared with the saline treated group. Time zero refers to the time right before cell or saline
injection. N=5 per group. (B): Serum NO levels in animals treated with L-NAME administered 60 min before MNC injection IV. 1p,0.05 refers to the
MNC group compared with the saline group; { p,0.05 refers to the MNC group compared with the L-NAME+MNC group. N=5 per group.
doi:10.1371/journal.pone.0032793.g002
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MNC-based therapy. Previous studies suggested that systemically
injected MNCs may be filtered by the lungs [13] and in this study
we found retention of more cells in the pulmonary artery with L-
NAME pre-treatment. We now determine that in addition to the
direct effect on MNC delivery to the brain, NO may facilitate
pulmonary transit of MNCs, as inhibition of NO with an NOS
inhibitor increased MNC retention in the lungs. Thus NO-
mediated transit via the lungs could allow for more MNC to reach
the brain to assist in damage repair after stroke. In agreement with
this notion, we demonstrated that MNC brain delivery in the
presence of L-NAME prevented MNCs from reducing infarct
maturation and neurological impairments. These results suggest a
pivotal role for NO in mediating the recovery effects of MNCs by
potentially facilitating their delivery in the brain where they
promote cytoprotective effects. Lastly, we also found that an NO
donor, administered instead of MNCs, does not lead to better
neurological outcome and attenuation of lesion size, which
provides further evidence for the importance of NO signaling as
a key mediator of MNC delivery to the brain and recovery from
stroke.
This study has a few limitations. The use of isoflurane for the
MR perfusion experiments may have been a complicating variable
since isoflurane increases CBF; alternative anesthesia may need to
be considered in future experiments. In addition, there are possibly
other mechanisms of MNCs that may contribute to their improved
long term recovery after stroke, beside NO-mediated MNC brain
penetration.
Figure 3. Time course of changes in cerebral perfusion after
administration of MNCs at 24 hours after stroke. Changes in
cerebral perfusion were measured with LDF over the peri-infarct region.
Animals at 24 hrs after stroke were treated with L-NAME or saline
60 min before administration of MNCs IV. A third group of control
animals received L-NAME followed by saline IV. 1p,0.05 refers to the
group pre-treated with saline followed by IV MNCs compared with the
group pre-treated with L-NAME followed by MNCs IV. ‘0’ on the x-axis
represents the time in minutes, just before the injection. N=5 per
group.
doi:10.1371/journal.pone.0032793.g003
Figure 4. Biodistribution of MNC in brain, spleen and lungs after IV administration of MNCs(10 million) at 24 hrs after stroke. MNCs
were labeled with Q-tracker(green). These animals had undergone stroke, 24 hrs later were injected with MNCs IV and then sacrificed 1 hr afterwards.
Sections were prepared at 1 hr after injection and counterstained with DAPI (blue). L-NAME was injected via IP 1 hr prior to MNC administration. N=3
per group. (A): Representative microscopic pictures illustrating MNCs (green+blue) in animals pre-treated with L-NAME (top row) or saline (bottom
row). Magnification: 4006. (B): A histogram illustrating the mean number of labeled MNCs per high power field in the brain, spleen, and lungs.
Animals were pre-treated with L-NAME before IV injection of MNCs or animals were pre-treated with saline followed by IV injection of MNCs
({p,0.05).
doi:10.1371/journal.pone.0032793.g004
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and IV delivery of MNCs in older rats 24 hrs after stroke
transiently increase CP within the peri-infarct region; (2) the
mechanisms underlying the changes in perfusion are likely due, at
least in part, to the effects of NO on cerebral vessels as MNCs
cause an increase in blood NO levels and a NOS inhibitor ablates
MNC effect of CP; (3) the increase in NO and CP is associated
with an increased delivery of MNCs to the brain and reduced
retention of MNCs in the lungs, as suggested by the reversal of this
effect by a NOS inhibitor. Finally, we propose that the delivery of
MNCs to the brain by NO may represent an important
mechanism underlying how MNCs access the brain to mediate
its effect on ischemic lesion maturation and improve recovery after
stroke. Our findings raise translational considerations that perhaps
an NO donor plus MNCs could enhance the efficacy of MNC-
based cell therapy for stroke.
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Figure 5. Illustration of a pulmonary artery of an animal pre-treated with L-NAME or Saline before IV MNC administration. Arrows
point toward Q tracker labeled MNCs.
doi:10.1371/journal.pone.0032793.g005
Figure 6. L-NAME inhibits the beneficial effect of MNCs. (A) Chronic infarct cavity at 28 days after stroke in animals treated with saline or
MNCs. Animals at 24 hrs after stroke received saline followed by IV MNCs (10 million cells), or L-NAME followed by IV MNCs (10 million cells), or saline
only. Lesion size was reduced by MNCs at 28 days after stroke. However, pre-treatment with L-NAME before MNC infusion abolished this reduction in
lesion size (1p,0.05 compared with saline). The lesion size was calculated as a percent of the contralateral cortex N=8 per group. (B) Neurological
deficits serially evaluated after stroke in animals treated with saline IP followed by IV infusion of MNCs or L-NAME IP followed by IV infusion of MNCs.
At 28 days, animals treated with saline followed by MNCs showed a significant reduction in deficits compared with animals treated with L-
NAME+MNCs or compared with animals treated with saline only (1p,0.05). The x-axis represents the time in days after stroke. Baseline refers to the
time point before stroke. N=8 per group.
doi:10.1371/journal.pone.0032793.g006
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